Alkermes (ALKS, Financial) experienced a significant stock price increase of 5.00%, reaching $31.72 per share with a trading volume of 928,667 shares and a turnover rate of 0.57%. The stock's price fluctuation was recorded at 6.54%.
Recent financial reports indicate that Alkermes achieved a revenue of $378 million and a net profit of $92.80 million, translating to an earnings per share of $0.57. The company also reported a gross profit of $314 million, with a price-to-earnings ratio of 16.02.
In terms of analyst ratings, 62% of the 13 institutions covering the stock recommend buying, 31% suggest holding, and 7% advise selling.
Within the pharmaceutical sector, where Alkermes operates, the overall growth was 0.72%. Notable performers in the sector include Amarin, Cbdmd, Inc., and Eton Pharmaceuticals, Inc., with high turnover rates observed in Inmed Pharmaceuticals Inc., Cbdmd, Inc., and Incannex Healthcare Inc. Stocks with significant price fluctuations include Cbdmd, Inc., Amarin, and Gelteq Limited.
Alkermes is a fully integrated biotechnology company focused on developing and commercializing pharmaceutical products to address unmet medical needs. The company employs various strategies to develop and commercialize its products, leveraging technical, financial, marketing, and manufacturing resources. Alkermes operates in the U.S., Ireland, and other regions, with the U.S. being its primary revenue source.
